top of page


Facilitate the implementation of Design of Experiments & Reduce in vivo assays


CYBERnano is developing a SaaS platform: i-Vivo to facilitate the implementation of statistical methods for the design of experiments and the reduction of in vivo assays. This platform is under construction and will be available after mid-2020.


[1] M. Toussaint, S. Pinel, F. Auger, N. Durieux, M. Thomassin, E. Thomas, A. Moussaron, D. Meng, F. Pl ́enat, M. Amouroux, T. T. Bastogne, C. Frochot, O. Tillement, F. Lux, and M. Barberi-Heyob, “Proton MR Spectroscopy and Diffusion MR Imaging Monitoring to Predict Tumor Response to Interstitial Photodynamic Therapy for Glioblastoma,” Theranostics, 2016.
[2] M. Pernot, N. P. E. Barry, T. Bastogne, C. Frochot, M. Barberi-Heyob, and B. Therrien, “Rational design of an arene ruthenium chlorin conjugate for in vivo anticancer activity,” Inorganica Chimica Acta, vol. 414, pp. 134–140, Apr. 2014.
[3] M. Pernot, T. Bastogne, N. P. E. Barry, B. Therrien, G. Koellensperger, S. Hann, V. Reshetov, and M. Barberi-Heyob, “System biology approach for in vivo photodynamic therapy optimization of ruthenium-porphyrin compounds,” Journal of Photochemistry and Photobiology B: Biology, vol. 117, pp. 80–89, Dec. 2012.
[4] V. Morosini, T. Bastogne, C. Frochot, R. Schneider, A. Fran ̧cois, F. Guillemin, and M. Barberi-Heyob, “Quantum Dot-folic acid conjugates as potential photosensitizers in photodynamic therapy of cancer,” Photochemical and Photobiological Sciences, vol. 10, pp. 842–851, May 2011.
[5] D. Bechet, L. Tirand, B. Faivre, F. Pl ́enat, C. Bonnet, T. Bastogne, C. Frochot, F. Guillemin, and M. Barberi Heyob, “Neuropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release,” Pharmaceutical Research / Pharmaceutical Research (Dordrecht), vol. 27, no. 3, pp. 468–479, 2010.
[6] L. Tirand, T. Bastogne, D. Bechet, M. Linder, N. Thomas, C. Frochot, F. Guillemin, and M. Barberi- Heyob, “Response surface methodology: an extensive potential to optimize photodynamic therapy condi- tions in vivo,” International Journal of Radiation Oncology, Biology, Physics, vol. 75, no. 1, pp. 244–252, 2009.
[7] J. Gravier, R. Schneider, C. Frochot, T. Bastogne, F. Schmitt, J. Didelon, F. Guillemin, and M. Barberi- Heyob, “Improvement of m-THPC-like photosensitizer selectivity with folate-based targeted delivery. Synthesis and in vivo selective delivery study,” Journal of Medicinal Chemistry, vol. 51, pp. 3867–3877, June 2008.

bottom of page